Core Points - Draganfly Inc. announced a public offering of 5,500,000 units at a price of US$2.50 per unit, aiming for gross proceeds of approximately US$13.75 million [1][3] - Each unit consists of one common share and one warrant, with the warrants having an exercise price of CA$5.0768 (or US$3.71) and expiring five years after issuance [1] - The net proceeds from the offering will be used for general corporate purposes, including funding new product capabilities, working capital, acquisitions, and research and development [3] Offering Details - The offering is expected to close on or about June 12, 2025, subject to customary closing conditions [3][4] - Maxim Group LLC is acting as the sole placement agent for the offering [2] - The offering is made under an effective shelf registration statement and a Canadian short form base shelf prospectus [5][6] Company Background - Draganfly Inc. is a pioneer in drone solutions, AI-driven software, and robotics, with over 25 years of innovation in the industry [8] - The company provides solutions for various sectors, including public safety, agriculture, industrial inspections, security, mapping, and surveying [8]

Core Viewpoint - Aduro Clean Technologies Inc. has announced a public offering of 947,868 common shares at a price of US$8.44 per share, aiming to raise approximately US$8 million for research and development, construction of a demonstration-scale plant, and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes 947,868 common shares and accompanying warrants to purchase 473,934 common shares, with each whole warrant exercisable at US$10.13 and expiring three years from issuance [1]. - The offering is managed by D. Boral Capital LLC as the sole book-running manager [2]. - An over-allotment option allows underwriters to purchase an additional 142,180 common shares and/or warrants for 71,090 common shares within 45 days [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to ongoing research and development costs, expenditures for the construction of a demonstration-scale plant, and any remaining funds for general corporate purposes and working capital [2]. Group 3: Regulatory Information - The offering is conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) and a Canadian short form base shelf prospectus [4]. - The base shelf prospectus has been filed with applicable securities commissions in Canada and the SEC, and is available for public access [5]. Group 4: Company Overview - Aduro Clean Technologies specializes in patented water-based technologies for recycling waste plastics, converting heavy crude into lighter oil, and transforming renewable oils into higher-value fuels or chemicals [7]. - The company's Hydrochemolytic™ Technology utilizes water as a key agent in a low-temperature chemistry platform, aiming to convert low-value feedstocks into valuable resources for the 21st century [7].

Core Viewpoint - AirSculpt Technologies, Inc. has announced a public offering of 3,160,000 shares of its common stock, with an additional option for underwriters to purchase up to 474,000 shares [1][2]. Group 1: Offering Details - The public offering consists of 3,160,000 shares of common stock, with a 30-day option for underwriters to buy an additional 474,000 shares [1]. - Vesey Street Capital Partners, the largest stockholder, is interested in purchasing up to $4.0 million in shares from the offering [2]. - Leerink Partners is acting as the sole bookrunner for the offering [3]. Group 2: Use of Proceeds - A portion of the net proceeds from the offering will be used to prepay part of the Company's outstanding debt under its existing credit agreement [3]. - The remaining proceeds will be allocated for general corporate purposes, including working capital and other business opportunities [3]. Group 3: Regulatory Information - A shelf registration statement for the shares was filed with the Securities and Exchange Commission and became effective on March 24, 2025 [4].

Core Viewpoint - Nuwellis, Inc. has announced a public offering of common stock and warrants to raise capital for working and corporate purposes, including potential acquisitions [1][2]. Group 1: Offering Details - The public offering includes 406,755 shares of common stock priced at $0.30 per share, along with pre-funded warrants for 14,085,998 shares priced at $0.2999 each [2]. - Accompanying the common stock are Series A Warrants for up to 43,478,259 shares and Series B Warrants for up to 14,492,753 shares, both with an exercise price of $0.30 [1][3]. - The offering is expected to close on or about June 10, 2025, subject to customary closing conditions [4]. Group 2: Warrant Details - Each pre-funded warrant has an exercise price of $0.0001 and is immediately exercisable until fully exercised [3]. - Series A and Series B Warrants will be exercisable for five years following stockholder approval, with Series A Warrants including a one-time reset of the exercise price under certain conditions [3]. - Series B Warrants offer a zero cash exercise option, allowing holders to receive shares without additional cash payment [3]. Group 3: Company Overview - Nuwellis, Inc. is a commercial-stage medical device company focused on treating fluid overload patients through innovative therapies [7]. - The company is commercializing the Aquadex SmartFlow system, which is designed for ultrafiltration therapy in patients unresponsive to medical management [8]. - Nuwellis is headquartered in Minneapolis and has a wholly owned subsidiary in Ireland [7].

Core Viewpoint - Helius Medical Technologies, Inc. has announced a public offering of 2,768,600 shares of Class A common stock and accompanying warrants, priced at $3.27 per share, aiming to raise approximately $9.1 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The public offering includes 2,768,600 shares of Class A common stock and warrants to purchase an equal number of shares at a combined price of $3.27 per share [1]. - Each warrant will expire in 2.5 years from issuance, is immediately exercisable at an initial price of $7.3575 per share, and can be exchanged for 2.0 common shares under a zero cash exercise option [2]. - The offering is expected to close on June 6, 2025, subject to customary closing conditions [3]. Group 2: Regulatory and Contact Information - A registration statement on Form S-1 was filed with the SEC and declared effective on June 4, 2025, with a final prospectus to be available on the SEC's website [4]. - Electronic copies of the prospectus can be obtained from Maxim Group LLC, the sole placement agent for the offering [4][7].

Group 1 - Orange County Bancorp, Inc. announced a public offering of 1,720,430 shares of common stock at a price of $23.25 per share, with an additional option for underwriters to purchase up to 258,064 shares [1][2] - The total gross proceeds from the offering are expected to be approximately $40.0 million, potentially increasing to $46.0 million if the underwriters fully exercise their option [2] - The net proceeds will be used for general corporate purposes, including investments in the Bank, enhancing regulatory capital and liquidity, and potential strategic acquisitions, although there are no current plans for specific acquisitions [2] Group 2 - The offering is expected to close on June 5, 2025, subject to customary closing conditions [2] - Piper Sandler & Co. and Stephens Inc. are acting as joint book-running managers for the offering [3] - Orange County Bancorp, Inc. is the parent company of Orange Bank & Trust Company, which has approximately $2.6 billion in total assets, and Hudson Valley Investment Advisors, Inc. [6]

Core Viewpoint - Orange County Bancorp, Inc. has launched an underwritten public offering of its common stock to support general corporate purposes, including investments in the Bank, regulatory capital, liquidity, and potential strategic acquisitions [1][2]. Group 1: Offering Details - The Company expects to grant underwriters a 30-day option to purchase additional shares of its common stock [1]. - The net proceeds from the offering will be used for general corporate purposes, which may include investments in the Bank, augmenting regulatory capital and liquidity, and potential strategic acquisitions [2]. Group 2: Regulatory Filings - The Company has filed a shelf registration statement and a preliminary prospectus supplement with the SEC for the offering [3]. - Investors are encouraged to read the preliminary prospectus supplement and accompanying prospectus for complete information about the Company and the offering [3]. Group 3: Company Background - Orange County Bancorp, Inc. is the parent company of Orange Bank & Trust Company and Hudson Valley Investment Advisors, Inc., with total assets of approximately $2.6 billion [5]. - Orange Bank & Trust Company has a history of over 125 years, focusing on community and business clientele [5].

Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [5] - Haduvio acts on the cough reflex arc as a kappa agonist and mu antagonist (KAMA), targeting opioid receptors involved in controlling chronic cough [5] Public Offering Details - Trevi Therapeutics has initiated an underwritten public offering of $100,000,000 of its common stock, with an additional option for underwriters to purchase up to $15,000,000 more [1] - The offering is being managed by Morgan Stanley, Leerink Partners, Stifel, and Cantor as joint book-running managers [2] - The shares are offered under a shelf registration statement filed with the SEC, which was declared effective on August 15, 2023 [3] Offering Conditions - The completion of the offering is subject to market and other conditions, with no assurance on the timing or terms of the offering [2] - A preliminary prospectus supplement detailing the terms of the offering is expected to be filed with the SEC [3]

Core Viewpoint - Femasys Inc. plans to conduct an underwritten public offering of its common stock, with an additional 30-day option for underwriters to purchase up to 15% more shares, alongside a concurrent private placement involving existing institutional stockholders and certain directors and officers [1][2]. Group 1: Offering Details - The public offering and private placement are subject to market conditions, with no assurance on completion timing or terms [2]. - Jones is the sole book-running manager for the public offering and placement agent for the private placement [3]. - The net proceeds from the offerings will be used for commercial expansion, product development, general corporate purposes, capital expenditures, and working capital [3]. Group 2: Regulatory Information - The securities are being offered under a Registration Statement on Form S-3, previously filed and declared effective by the SEC [4]. - The private placement will rely on an exemption from registration under the Securities Act, meaning the securities may not be sold in the U.S. without an effective registration statement or applicable exemption [4]. Group 3: Company Overview - Femasys Inc. focuses on women's health, developing minimally invasive, in-office technologies for reproductive health, including products like FemBloc for permanent birth control and FemaSeed for infertility [6]. - Current marketed products include FemVue for fallopian tube assessment and FemCath, an intrauterine catheter for selective evaluation [6].

Core Viewpoint - Immunic, Inc. has initiated an underwritten public offering of various warrants to purchase shares of common stock, aimed at funding clinical trials and operations for its pipeline of therapies targeting chronic inflammatory and autoimmune diseases [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants, Series A warrants expiring on December 31, 2025, and Series B warrants expiring five years after issuance [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. - Leerink Partners is acting as the sole bookrunner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund clinical trials, operations, and other general corporate purposes [2]. Group 3: Company Overview - Immunic, Inc. is focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [5]. - The lead program, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [5]. - Vidofludimus calcium has shown therapeutic activity in earlier phase 2 trials and works as a first-in-class nuclear receptor related 1 (Nurr1) activator [5]. - Other candidates include IMU-856, targeting gastrointestinal diseases, and IMU-381, currently in preclinical testing [5].